Orforglipron is the active ingredient in Foundayo, an oral GLP-1 medicine approved by FDA for adult weight management on 1 April 2026. Calling it simply “experimental” misses that change. But an approval headline does not explain how much benefit was observed, who was studied or why two reports might quote different results. This guide reads those details together.
Begin with the product, country and purpose
The FDA approval letter establishes the US decision. The reviewed July 2026 prescribing information describes weight reduction and long-term maintenance with dietary and activity support for adults with obesity, or overweight plus a weight-related condition. It does not make every proposed use approved.
Before applying a headline to a care decision, write down its country, product, indication and source date. “An oral medicine has trial results” and “this product has a particular approved use here” answer different questions. Availability, cost and coverage require separate local checks. Our orforglipron profile provides a compact product reference; this article concentrates on reading the evidence.
What the two approval trials actually compared
Section 14 of the initial FDA label describes two 72-week randomised, double-blind trials with placebo and lifestyle support in every group. Trial 1 enrolled 3,127 adults with obesity, or overweight and a related condition, excluding type 2 diabetes. Trial 2 enrolled 1,613 adults with BMI at least 27 and type 2 diabetes. These populations should remain separate when comparing results.
| Population | Orforglipron arms, lower to higher equivalent strength | Placebo |
|---|---|---|
| Trial 1, without type 2 diabetes | 7.4%, 8.3%, 11.1% | 2.1% |
| Trial 2, with type 2 diabetes | 5.1%, 7.0%, 9.6% | 2.5% |
The three active arms correspond to equivalent approved-formulation strengths of 5.5, 9 and 17.2 mg. These identify study groups, not a starting dose or instructions for choosing treatment. The trials used an investigational formulation; the label bridges its findings to the approved tablets. Do not convert old research quantities into a personal regimen.
Read the comparison, not just the largest number
For the highest equivalent-strength arm in Trial 1, the label reports a 9.0 percentage-point estimated difference from placebo, with a 95% confidence interval of 8.1–10.0 points in favour of treatment. The difference compares groups. It is not a promise that every participant lost the same amount, and it does not mean “9% more people” achieved a particular threshold.
To check a result yourself, keep its description attached: average percentage weight change, study population, comparison group and follow-up time. A percentage of starting weight and a percentage of participants achieving a threshold are different outcomes. A news report may use either. If the outcome has changed between headlines, the numbers cannot be lined up as though they measure the same thing.
The label’s intent-to-treat table includes all randomised participants and uses statistical methods for missing measurements. It is not a table limited to people who completed every visit while continuing treatment. Missing data introduce assumptions; including all randomised participants does not mean every final weight was directly measured. Check the table footnotes when a result looks more precise than the underlying follow-up supports.
This also explains why an advertisement, conference report or paper may show another percentage without necessarily contradicting the label. Look for the analysis question: does it estimate an effect under continued treatment, or account for treatment changes and discontinuation differently? Do not select the biggest estimate and attach it to an unrelated population. Our trial-reading guide explains these comparisons in more detail.
What these trials cannot settle on their own
A placebo-controlled weight trial does not by itself establish superiority over another active medicine. Comparing its average with a number from a different study introduces differences in participants, support, follow-up and analysis. Even a later direct comparison would need its own population and methods checked; it would not make every previous cross-trial ranking reliable.
Likewise, a change in body weight is not automatically evidence of a particular reduction in heart attacks, improved survival or benefit in every condition associated with weight. Each claim needs a matching outcome and source. Ask “what was actually measured?” before turning a weight result into a broader health promise.
The studies also do not answer what your own experience will be. The practical decision combines relevant evidence with medical history, preferences, tolerability, nutrition, daily routine and access. An oral option may fit some routines better, but convenience alone cannot resolve those questions.
Put tolerability beside efficacy
Across the two trials, the July label reports treatment discontinuation because of adverse reactions in 8% of treated participants versus 3% receiving placebo. Nausea was reported in 26–35% across active arms versus 10% with placebo. These are pooled trial observations, not an individual’s predicted risk. The label cautions against directly comparing adverse-event rates across separate drug trials. FDA label, section 6.
The same label includes a boxed thyroid warning, contraindications involving medullary thyroid carcinoma or MEN 2, and other important precautions. Medication interactions, pregnancy and oral contraception require particular attention. A tablet does not remove these issues. Read the current product information with the prescribing team rather than using this evidence summary as a safety checklist or dosing guide.
Keep the European assessment separate
The reviewed 12–15 October 2026 CHMP draft agenda lists orforglipron under opinions for adoption. An agenda describes planned committee work; it does not verify the meeting outcome or a European Commission marketing authorisation. Those later decisions are not established by the sources reviewed here. Check the actual final regulator record before making an EU approval claim.
Five questions to take to a consultation
- Which approved use and local product information apply to the decision we are discussing?
- Which trial population is most relevant to my history, and which result are we using?
- What benefit would matter in my daily life, beyond a headline weight percentage?
- Which tolerability issues, interactions and follow-up needs should we discuss?
- What is our plan if treatment is difficult to tolerate or obtain?
Record the answers and anything still uncertain. The appointment worksheet can help turn those questions into a follow-up plan. The purpose is a better-informed conversation, rather than choosing a treatment from a league table of trial averages.



